In summary, while CD24-targeted immunotherapy holds promise in the treatment of cancer and non-neoplastic diseases, numerous questions related to its clinical application, efficacy, safety, and combination strategies still need to be addressed through rigorous research and clinical trials. This evidence concerns the gene CD24 and neoplasm.